Jade Biosciences is developing JADE101, a selective APRIL inhibitor for IgA nephropathy (IgAN), aiming for quarterly dosing to improve patient adherence compared to competitors. Phase 1 data show JADE101 reduces IgA levels by about 70% with a good safety profile. The upcoming Phase 2 JUNIPER trial interim results, expected in 2027, will be critical for the drug's future. The company also has other candidates designed for extended dosing intervals, supported by $461 million in cash to fund development through 2028, though risks remain from clinical translation and competition.
Viking Holdings reported better-than-expected Q2 earnings with revenue up 16.5% to $2.19 billion and EPS of $1.31, beating estimates. The growth was driven by adding seven river and two ocean vessels, increasing passenger cruise days by 10.9%. Howeve...
Belden, Inc. reported a record second-quarter revenue of $750.20 million, driven by its role as a key supplier in AI infrastructure. Analysts raised the price target to $170, suggesting a potential 31.68% upside from the current price of around $129....
Director Carande has purchased 2,101 shares of United Community Banks. This insider buying may indicate confidence in the company's future prospects. Investors often view such transactions as a positive signal, potentially influencing market sentimen...
Bio-Techne reported Q4 revenues of $321.2 million, slightly surpassing estimates, but its adjusted EPS fell 1.9% year-over-year to $0.52, showing mixed financial results. The company's stock remains close to Merck KGaA's $73 per share acquisition off...
Estée Lauder reported quarterly earnings per share of $0.39, surpassing analyst estimates of $0.32, and revenue of $3.62 billion, exceeding expectations. The company showed 5% organic sales growth for the fourth consecutive quarter and raised its ful...
